Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,860 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04642937 | Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma | unknown | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05381181 | Safety and Efficacy Evaluation of Next-generation CD19-UCART | unknown | Phase 1 | 20 | Bioray LaboratoriesINDUSTRY | 0 | Jan 27, 2023 | clinicaltrials |
| NCT05698303 |
| A Study of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (CT103A) in the Treatment of Patients With Relapsed/Refractory Multiple Myeloma |
| unknown |
| Phase 1 |
| 12 |
| Nanjing IASO Biotechnology Co., Ltd.INDUSTRY |
| 1 |
| Jan 26, 2023 |
| clinicaltrials |
| NCT05700955 | Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 30 | University of LouisvilleOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT02981108 | A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC | unknown | Phase 1 / Phase 2 | 364 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05533203 | Safety of Prodencel in the Treatment of Metastatic Castration-resistant Prostate Cancer (mCRPC) | unknown | Phase 1 | 24 | Shanghai Humantech Biotechnology Co. LtdINDUSTRY | 1 | Jan 23, 2023 | clinicaltrials |
| NCT05234853 | Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors | unknown | Phase 1 | 23 | Purinomia Biotech, Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05537987 | Evaluate the Safety, Tolerability, and Pharmacokinetics of ICP-723 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | InnoCare Pharma Inc.INDUSTRY | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05692661 | A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer | unknown | Phase 1 | 24 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT05691153 | ThisCART19A for B-NHL Relapsed After Auto-CAR T | unknown | Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 19, 2023 | clinicaltrials |
| NCT04582968 | Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases | unknown | Phase 1 / Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT04900519 | Study of the Safety and Efficacy of STI-6643 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 100 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05007418 | Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 54 | Sorrento Therapeutics, Inc.INDUSTRY | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05679687 | ThisCART19A Bridging to alloHSCT for R/R B-ALL | unknown | Phase 1 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 11, 2023 | clinicaltrials |
| NCT05673538 | TT-00973-MS Tablets in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05642949 | Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 400 | Minghui Pharmaceutical Pty LtdINDUSTRY | 1 | Jan 9, 2023 | clinicaltrials |
| NCT05540873 | A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) | unknown | Phase 1 | 18 | CellabMEDINDUSTRY | 1 | Jan 6, 2023 | clinicaltrials |
| NCT05665075 | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia | unknown | Phase 1 | 19 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT05665114 | Natural Killer(NK) Cell Therapy in r/r AML | unknown | Phase 1 | 18 | Zhejiang UniversityOTHER | 1 | Jan 3, 2023 | clinicaltrials |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | unknown | Phase 1 / Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04385173 | Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma | unknown | Phase 1 | 12 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05666635 | Study of LTC004 in Subjects With Advanced Malignant Tumors | unknown | Phase 1 | 368 | LetolabINDUSTRY | 0 | Dec 28, 2022 | clinicaltrials |
| NCT03775525 | Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer(GEN602) | unknown | Phase 1 | 127 | Genzada Pharmaceuticals USA, Inc.INDUSTRY | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05663125 | LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas | unknown | Phase 1 / Phase 2 | 10 | Beijing Tiantan HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05654038 | A Study of Universal CD19-Targeted UCAR-NK Cells Combined With HSCT for B Cell Hematologic Malignancies | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 21, 2022 | clinicaltrials |
| NCT04612530 | PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer | unknown | Phase 1 | 18 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05649761 | A Phase I Study of QL1604 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 61 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05650385 | A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors | unknown | Phase 1 | 68 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05651100 | Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma | unknown | Phase 1 / Phase 2 | 50 | Kecellitics Biotech Company LtdINDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04614740 | The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | unknown | Phase 1 / Phase 2 | 115 | Jiangsu vcare pharmaceutical technology co., LTDINDUSTRY | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05557851 | Minnelide Along With Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the Pancreas | unknown | Phase 1 | 36 | Minneamrita Therapeutics LLCINDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05644509 | Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor | unknown | Phase 1 | 10 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05645315 | Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 127 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05639179 | Novel Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL | unknown | Phase 1 / Phase 2 | 30 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05643417 | Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy | unknown | Phase 1 | 80 | Fudan UniversityOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04433494 | A Study of TY-302 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | TYK Medicines, IncINDUSTRY | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03142204 | [18F]FAraG PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy and/or Radiation Therapy | unknown | Phase 1 | 30 | CellSight Technologies, Inc.INDUSTRY | 1 | Dec 5, 2022 | clinicaltrials |
| NCT04450901 | Dose Escalation/Dose Expansion Study of YBL-006 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 90 | Y Biologics Inc.INDUSTRY | 3 | Dec 5, 2022 | clinicaltrials |
| NCT04100187 | Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia | unknown | Phase 1 | 100 | Kecellitics Biotech Company LtdINDUSTRY | 0 | Dec 1, 2022 | clinicaltrials |
| NCT05338957 | A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors. | unknown | Phase 1 / Phase 2 | 30 | Shanghai Miracogen Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05266768 | Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of IBI346#CIBI346Y002# | unknown | Phase 1 | 36 | Chunrui LiOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT04472858 | A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT04503902 | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 1 / Phase 2 | 46 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05205408 | A Study of Intratumoral Administration of Oncolytic Virus Injection (RT-01) in Patients With Advanced Solid Tumors | unknown | Phase 1 | 7 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05622825 | Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers | unknown | Phase 1 / Phase 2 | 15 | National Taiwan University HospitalOTHER | 0 | Nov 21, 2022 | clinicaltrials |
| NCT05622227 | 68Ga PET/CT Imaging in Breast Cancer Patients | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05620654 | A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin | unknown | Phase 1 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT04976218 | TGFβR-KO CAR-EGFR T Cells in Previously Treated Advanced EGFR-positive Solid Tumors | unknown | Phase 1 | 30 | Chinese PLA General HospitalOTHER | 1 | Nov 16, 2022 | clinicaltrials |
Data updated 24 days agoSource updated Jan 27, 2023source: clinicaltrials